Logo image of HCP

HASHICORP INC-CL A (HCP) Stock Fundamental Analysis

NASDAQ:HCP - Nasdaq - US4181001037 - Common Stock - Currency: USD

34.5  +0.02 (+0.06%)

After market: 34.26 -0.24 (-0.7%)

Fundamental Rating

5

Taking everything into account, HCP scores 5 out of 10 in our fundamental rating. HCP was compared to 284 industry peers in the Software industry. HCP has a great financial health rating, but its profitability evaluates not so good. HCP is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year HCP was profitable.
In the past year HCP had a positive cash flow from operations.
HCP had negative earnings in each of the past 5 years.
HCP had a negative operating cash flow in each of the past 5 years.
HCP Yearly Net Income VS EBIT VS OCF VS FCFHCP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

Looking at the Return On Assets, with a value of -7.22%, HCP is in line with its industry, outperforming 42.75% of the companies in the same industry.
Looking at the Return On Equity, with a value of -9.72%, HCP is in line with its industry, outperforming 48.19% of the companies in the same industry.
Industry RankSector Rank
ROA -7.22%
ROE -9.72%
ROIC N/A
ROA(3y)-15.33%
ROA(5y)-17.17%
ROE(3y)-20.37%
ROE(5y)-30.92%
ROIC(3y)N/A
ROIC(5y)N/A
HCP Yearly ROA, ROE, ROICHCP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40 -50

1.3 Margins

The Gross Margin of HCP (82.09%) is better than 86.59% of its industry peers.
In the last couple of years the Gross Margin of HCP has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for HCP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 82.09%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.31%
GM growth 5Y-0.29%
HCP Yearly Profit, Operating, Gross MarginsHCP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

8

2. Health

2.1 Basic Checks

HCP does not have a ROIC to compare to the WACC, probably because it is not profitable.
HCP has more shares outstanding than it did 1 year ago.
There is no outstanding debt for HCP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
HCP Yearly Shares OutstandingHCP Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 50M 100M 150M
HCP Yearly Total Debt VS Total AssetsHCP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

HCP has an Altman-Z score of 9.72. This indicates that HCP is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of HCP (9.72) is better than 81.16% of its industry peers.
There is no outstanding debt for HCP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 9.72
ROIC/WACCN/A
WACC13.99%
HCP Yearly LT Debt VS Equity VS FCFHCP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

A Current Ratio of 3.79 indicates that HCP has no problem at all paying its short term obligations.
HCP has a better Current ratio (3.79) than 81.88% of its industry peers.
A Quick Ratio of 3.79 indicates that HCP has no problem at all paying its short term obligations.
HCP has a Quick ratio of 3.79. This is amongst the best in the industry. HCP outperforms 81.88% of its industry peers.
Industry RankSector Rank
Current Ratio 3.79
Quick Ratio 3.79
HCP Yearly Current Assets VS Current LiabilitesHCP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

7

3. Growth

3.1 Past

HCP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 247.62%, which is quite impressive.
Looking at the last year, HCP shows a quite strong growth in Revenue. The Revenue has grown by 16.30% in the last year.
HCP shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 61.00% yearly.
EPS 1Y (TTM)247.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%333.33%
Revenue 1Y (TTM)16.3%
Revenue growth 3Y40.14%
Revenue growth 5Y61%
Sales Q2Q%18.66%

3.2 Future

Based on estimates for the next years, HCP will show a very strong growth in Earnings Per Share. The EPS will grow by 118.92% on average per year.
HCP is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.50% yearly.
EPS Next Y509.24%
EPS Next 2Y171.61%
EPS Next 3Y118.92%
EPS Next 5YN/A
Revenue Next Year17.24%
Revenue Next 2Y14.94%
Revenue Next 3Y15.5%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
HCP Yearly Revenue VS EstimatesHCP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M
HCP Yearly EPS VS EstimatesHCP Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 -0.5

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 111.29 indicates a quite expensive valuation of HCP.
Compared to the rest of the industry, the Price/Earnings ratio of HCP is on the same level as its industry peers.
When comparing the Price/Earnings ratio of HCP to the average of the S&P500 Index (29.63), we can say HCP is valued expensively.
HCP is valuated quite expensively with a Price/Forward Earnings ratio of 71.29.
HCP's Price/Forward Earnings is on the same level as the industry average.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.68, HCP is valued quite expensively.
Industry RankSector Rank
PE 111.29
Fwd PE 71.29
HCP Price Earnings VS Forward Price EarningsHCP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

HCP's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 123.32
EV/EBITDA N/A
HCP Per share dataHCP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

HCP's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as HCP's earnings are expected to grow with 118.92% in the coming years.
PEG (NY)0.22
PEG (5Y)N/A
EPS Next 2Y171.61%
EPS Next 3Y118.92%

More info and screens

0

5. Dividend

5.1 Amount

HCP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HASHICORP INC-CL A

NASDAQ:HCP (2/21/2025, 8:25:15 PM)

After market: 34.26 -0.24 (-0.7%)

34.5

+0.02 (+0.06%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)12-05 2024-12-05/amc
Earnings (Next)03-06 2025-03-06/amc
Inst Owners79.69%
Inst Owner Change-87.32%
Ins Owners3.97%
Ins Owner Change5.96%
Market Cap7.05B
Analysts69.23
Price Target35.32 (2.38%)
Short Float %5.31%
Short Ratio3
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1179.36%
Min EPS beat(2)163.27%
Max EPS beat(2)2195.45%
EPS beat(4)4
Avg EPS beat(4)814.28%
Min EPS beat(4)163.27%
Max EPS beat(4)2195.45%
EPS beat(8)8
Avg EPS beat(8)447.11%
EPS beat(12)12
Avg EPS beat(12)310.7%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)4.35%
Min Revenue beat(2)3.98%
Max Revenue beat(2)4.72%
Revenue beat(4)4
Avg Revenue beat(4)3.95%
Min Revenue beat(4)3.32%
Max Revenue beat(4)4.72%
Revenue beat(8)8
Avg Revenue beat(8)3.78%
Revenue beat(12)12
Avg Revenue beat(12)5.75%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.2%
EPS NQ rev (1m)25.26%
EPS NQ rev (3m)49.23%
EPS NY rev (1m)8.02%
EPS NY rev (3m)42.14%
Revenue NQ rev (1m)1.34%
Revenue NQ rev (3m)1.62%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.77%
Valuation
Industry RankSector Rank
PE 111.29
Fwd PE 71.29
P/S 10.77
P/FCF 123.32
P/OCF 103.68
P/B 5.61
P/tB 5.71
EV/EBITDA N/A
EPS(TTM)0.31
EY0.9%
EPS(NY)0.48
Fwd EY1.4%
FCF(TTM)0.28
FCFY0.81%
OCF(TTM)0.33
OCFY0.96%
SpS3.2
BVpS6.15
TBVpS6.05
PEG (NY)0.22
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.22%
ROE -9.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 82.09%
FCFM 8.73%
ROA(3y)-15.33%
ROA(5y)-17.17%
ROE(3y)-20.37%
ROE(5y)-30.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.31%
GM growth 5Y-0.29%
F-Score6
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 84.44%
Cap/Sales 1.65%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.79
Quick Ratio 3.79
Altman-Z 9.72
F-Score6
WACC13.99%
ROIC/WACCN/A
Cap/Depr(3y)195.54%
Cap/Depr(5y)361.24%
Cap/Sales(3y)2%
Cap/Sales(5y)2.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)247.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%333.33%
EPS Next Y509.24%
EPS Next 2Y171.61%
EPS Next 3Y118.92%
EPS Next 5YN/A
Revenue 1Y (TTM)16.3%
Revenue growth 3Y40.14%
Revenue growth 5Y61%
Sales Q2Q%18.66%
Revenue Next Year17.24%
Revenue Next 2Y14.94%
Revenue Next 3Y15.5%
Revenue Next 5YN/A
EBIT growth 1Y37.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year118.63%
EBIT Next 3Y44.51%
EBIT Next 5YN/A
FCF growth 1Y156.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y173.12%
OCF growth 3YN/A
OCF growth 5YN/A